SCHEMBL2917792

SCHEMBL2917792

C[C@H]1C[C@@H](O)CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.51
CHRM2 P08172 1/20 0.47
CHRM1 P11229 1/20 0.47
CHRM3 P20309 1/20 0.47
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HPGD P15428 1/20 0.40
EPHX2 P34913 1/20 0.39
KDM4E B2RXH2 1/20 0.39
RECQL P46063 1/20 0.38
EPHX1 P07099 1/20 0.38
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
NAMPT P43490 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
RORC P51449 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2917795 1.00 NR1H2 (0.51) NR1H2CHRM2CHRM1CHRM3USP2
SCHEMBL18383163 1.00 NR1H2 (0.51) NR1H2CHRM2CHRM1CHRM3USP2
SCHEMBL29105803 1.00 NR1H2 (0.51) NR1H2CHRM2CHRM1CHRM3USP2
SCHEMBL29105861 1.00 NR1H2 (0.51) NR1H2CHRM2CHRM1CHRM3USP2
SCHEMBL2917798 1.00 NR1H2 (0.51) NR1H2CHRM2CHRM1CHRM3USP2
SCHEMBL22413119 0.89 NR1H2 (0.57) NR1H2CHRM2CHRM1CHRM3USP2
SCHEMBL22413118 0.89 NR1H2 (0.57) NR1H2CHRM2CHRM1CHRM3USP2
SCHEMBL22720484 0.89 NR1H2 (0.57) NR1H2CHRM2CHRM1CHRM3USP2
SCHEMBL31433037 0.89 NR1H2 (0.57) NR1H2CHRM2CHRM1CHRM3USP2
SCHEMBL15139606 0.89 NR1H2 (0.57) NR1H2CHRM2CHRM1CHRM3USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026736-A1 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof NOVARTIS AG (CH) 2025-01-23 US disclosed
US-12103919-B2 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2024-10-01 US disclosed
CN-117062811-A 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and medical use thereof 诺华股份有限公司 2023-11-14 CN disclosed
US-20230019617-A1 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof NOVARTIS AG (CH) 2023-01-19 US disclosed
US-20210300940-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2021-09-30 US disclosed
US-10906888-B2 Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme PFIZER INC. (US) 2021-02-02 US disclosed
WO-2020025517-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2020-02-06 WO disclosed
US-20190315715-A1 NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME PFIZER INC. (US) 2019-10-17 US disclosed
EP-2010506-B1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS HOFFMANN LA ROCHE (CH) 2010-08-04 EP disclosed
US-7632829-B2 Diazepan derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-15 US disclosed
EP-2010506-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-Roche AG (CH) 2009-01-07 EP disclosed
WO-2007122103-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-01 WO disclosed
US-20070249589-A1 Novel diazepan derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026736-A1 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof HBZ, HBG1, HBG2 NR1H2 734/4885CHRM2 4722/4885CHRM1 4635/4885
US-20230019617-A1 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof HBZ, HBG1, HBG2 NR1H2 734/4885CHRM2 4722/4885CHRM1 4635/4885
US-12103919-B2 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof HBZ, HBG1, HBG2 NR1H2 734/4885CHRM2 4722/4885CHRM1 4635/4885
US-20070249589-A1 Novel diazepan derivatives CCR3, CCR1, CCR10 NR1H2 188/4885CHRM2 33/4885CHRM1 40/4885
US-20190315715-A1 NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME VNN1, DPYD, MVD NR1H2 4738/4885CHRM2 3041/4885CHRM1 2261/4885
US-10906888-B2 Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme VNN1, DPYD, MVD NR1H2 4753/4885CHRM2 2944/4885CHRM1 2117/4885
US-20210300940-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 NR1H2 37/4885CHRM2 2432/4885CHRM1 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.